The Phase III trial failed to meet its co-primary endpoints or any of its key secondary endpoints. Credit: Ton Photographer 4289 / Shuttertock.com Kolon TissueGene’s stock has dropped after a Phase ...

If approved, Keenova's Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.

Following a turbulent funding environment, biotechs are seeking to generate more data earlier to reassure investors.

Trellis Bioscience has closed a $9m Series C round to support the completion of its ongoing Phase II trial evaluating calpurbatug for chronic PJI.

GSK will discontinue camlipixant’s late-stage RCC programme, though it will continue the drug’s development in two forms of IBS.

When the FDA approved Madrigal's Rezdiffra in 2024, it was the first marketed drug ever for MASH, which affects millions of American adults.

Ipsen claims that Dysport has become the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.

Arrowhead's EU authorisation of Redemplo expands targeted FCS treatment as the competitive apoC-III landscape continues to evolve.

Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a Phase III trial of Wainua (eplontersen) in transthyretin-mediated amy ...

Precemtabart tocentecan is also being investigated in other oncology indications including gastric cancer, non-small cell lung cancer and pancreatic ductal ...